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Tuesday, March 8, 2011 421apotential upstroke. These data are the first report of FGF13 as regulator ofNav1.5
in heart and suggest that FGF13 isoform-specific regulation of cardiac Nav chan-
nels plays important physiological and pathophysiological roles.
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CaMKII Regulates Cardiac Sodium Channel Nav1.5 by Phosphorylation
in the Loop Between Domain I and II
Anthony W. Herren, Nicole M. Ashpole, Kenneth S. Ginsburg,
Donald M. Bers, Andy Hudmon.
The cardiac Na channel NaV1.5 current (INa) is critical to cardiac excitability
and altered INa gating has been implicated in genetic and acquired arrhyth-
mias. Ca-calmodulin dependent protein kinase (CaMKII) is upregulated in
heart failure and has been shown to cause INa gating changes that mimic
a point mutant in humans associated with combined long QT and Brugada
syndromes. We sought to identify the CaMKII phosphorylation target site
on NaV1.5 that mediates the CaMKII-induced alterations in INa gating. We an-
alyzed CaMKII-dependent phosphorylation of NaV1.5 intracellularly accessi-
ble sites using a series of GST-fusion constructs, immobilized peptide arrays,
and soluble peptides. CaMKII phosphorylation sites were identified at S516
and S593/T594 in the intracellular NaV1.5 loop between domains 1 and 2.
Wild-type (WT) and phospho-mutant human Nav1.5 were co-expressed
with CaMKIIdC-GFP in HEK293 cells and INa was recorded by whole-cell
patch clamp under pipette conditions that acutely activated CaMKII (þ1
mM free [Ca], þ 1 mM Calmodulin). As observed in myocytes, CaMKII
shifted WT INa availability to more negative membrane potentials and en-
hanced accumulation of INa into intermediate inactivation, but these effects
were abolished by mutating either of the CaMKII sites to non-
phosphorylatable alanine residues (V1/2 of availability: WT 101.8 5 4.5
(n=10); S593/T594AA 89.7 5 3.5 (n=11) ; S516A 93.0 5 5.5 (n=18)).
Furthermore, the phospho-mutant channels mimicked WT INa treated with 1
mM AIP, a specific CaMKII inhibitor, and AIP had no effect on phospho-
mutant INa. CaMKII activation had no effect on the V1/2 of activation or I-
V curve shape of any channel. CaMKII-dependent phosphorylation of
NaV1.5 at multiple sites (including Ser593/Thr594 and Ser516) appears to
be required to evoke loss-of-function changes in gating that could contribute
to acquired Brugada syndrome like effects in heart failure.
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Chlorobutanol, a Pharmaceutical Preservative and Sedative Hypnotic,
Inhibits Brain Type Voltage Gated Sodium Channels
George Kracke, Alice Landrum.
Introduction- Chlorobutanol (1,1,1-trichloro-2-methyl-2-propanol) is a widely
used chemical preservative for injectabledrugs, eyedrops,mouthwashes, and cos-
metics. It is ananalgesic, experimental general anesthetic, and sedativehypnotic in
man. The mechanism of action of chlorobutanol is unclear. Our goal was to test
whether chlorobutanol inhibits brain type voltage gated sodium channels.
Methods- Mammalian Nav 1.2 voltage gated sodium channels were expressed
in Xenopus oocytes by injecting the alpha subunit cRNA. Inward sodium cur-
rents were measured with two-electrode voltage clamp using standard depolar-
ization protocols. The study was approved by our institutional animal care and
use committee.
Results- Chlorobutanol was tested at concentrations ranging from 0.03 to 10
mM. Chlorobutanol reversibly inhibited closed, resting channels and inacti-
vated channels in a concentration dependent manner. The voltage dependence
of activation was shifted in the depolarizing direction. Fast inactivation voltage
dependence was not affected. There was little state dependent block and no ap-
parent use dependence.
Discussion and Conclusions- Chlorobutanol inhibited Nav 1.2 channels at con-
centrations less than those used to preserve pharmaceuticals. Its use as a preser-
vative in injectable methadone and local anesthetic solutions, and in eye drops
likely adds an analgesic component to these solutions.
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Enhancement of Slow Inactivation of Voltage-Gated Naþ Channels by
Ranolazine
Ryoko Hirakawa, Lynda V. Liu, John C. Shryock, Luiz Belardinelli,
Sridharan Rajamani.
Ranolazine is an anti-anginal drug that blocks cardiac (Nav1.5) late Na
þ current
(INa) at therapeutic concentrations (2-10 mM). Recent electrophysiological
studies have shown that ranolazine also blocks skeletal muscle (Nav1.4) and
neuronal (Nav1.1, Nav1.7, Nav1.8) INa. We investigated the effects of ranola-
zine on peak INa and on both sustained repetitive firing (SRF) and 0 mM
Mg2þ- induced (0 [Mg2þ]O) continuous high frequency firing of action poten-
tials in cultured rat hippocampal neurons. Ranolazine caused a voltage (60
mV) and frequency (10 Hz)-dependent inhibition of INa with IC50 values of0.48 and 61.8 mM (n=4-6), respectively.
Ranolazine (10 mM, n=4) did not shift
the voltage-dependence of steady-state
fast inactivation; however, it caused
a 15-mV hyperpolarizing shift
(p<0.05, compared to control, n=4) in
the slow inactivation. Consistently, ra-
nolazine (10 mM) reduced SRF only
during a 4-sec burst but not with a 1-
sec depolarization step (Fig.1). Further-
more, ranolazine (10 mM) reduced
0 [Mg2þ]O -induced high frequency fir-
ing of spontaneous action potentials
from 0.78 to 0.45 Hz (p<0.05, n=5). Taken together, these data suggest that ra-
nolazine suppresses the propagation and conduction of action potentials by
preferentially interacting with Naþ channels in the slow inactivated state.
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Y1767C, a Novel SCN5A Mutation Induces a Persistent Sodium Current
and Potentiates Ranolazine Inhibition of NaV1.5 Channels
Hai Huang, Silvia G. Priori, Carlo Napolitano, Michael E. O’Leary,
Mohamed Chahine.
LongQT syndrome type 3 (LQT3) has been traced tomutations of the cardiacNa
channel (Nav1.5) that produce persistent Na currents leading to delayed ventric-
ular repolarization and Torsades de pointes. We performed mutational analyses
of patients suffering from LQTS and characterized the biophysical properties of
the mutations that we uncovered. One LQT3 patient carried a mutation in the
SCN5A gene in which the cysteine was substituted for a highly conserved tyro-
sine (Y1767C) located near cytoplasmic entrance of the Nav1.5 channel pore.
The wild-type and mutant channels were transiently expressed in tsA201 cells,
and the Na currents were recorded using the patch-clamp technique. The
Y1767C channel produced a persistent Na current, more rapid inactivation,
faster recovery from inactivation, and an increased window current. The persis-
tent Na current of the Y1767C channel was blocked by ranolazine but not by
many class I antiarrhythmic drugs. The incomplete inactivation, along with
the persistent activation of Na channels caused by an overlap of voltage-
dependent activation and inactivation, known as window currents, appeared to
contribute to the LQTS phenotype in this patient. The blocking effect of ranola-
zine on the persistent Na current suggested that ranolazine may be an effective
therapeutic for treating patients with this mutation. Our data also revealed the
unique role for the Y1767 residue in inactivating and forming the intracellular
pore of the Nav1.5 Na channel.
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The Selective Nav1.8 Sodium Channel Blocker A-803467 Affects Electrical
Activity in Intracardiac Neurons, but not in Cardiomyocytes
Marieke W. Veldkamp, Carol A. Remme, Brendon Scicluna,
Cees A. Schumacher, Rianne Wolswinkel, Antoni C.G. van Ginneken,
Connie R. Bezzina, Arie O. Verkerk.
Background. Recently we observed differential myocardial expression of the
brain-type sodium channel isoform Scn10a between two inbred mouse strains,
both harboring the Scn5a-1798insDþ/- mutation and displaying different se-
verity of conduction disease. The functional role of Scn10a in the heart is as
yet unknown, and we therefore investigated expression and channel activity
of NaV1.8 (encoded by Scn10a) in intracardiac neurons and myocardium of
the murine heart.
Methods. Immunocytochemistry was performed using anti-NaV1.8 antibody
on mouse embryos and adult murine cardiac tissue sections. The effect of the
NaV1.8 blocker A-803467 (500 nM) on action potentials (AP’s) and sodium
current (INa) properties was assessed in isolated intracardiac neurons and ven-
tricular myocytes.
Results. In embryonic and adult heart tissue sections, NaV1.8 staining was ob-
served at the epicardial surface, and within the myocardium in between cardio-
myocytes. The NaV1.8 blocker A-803467 had no effect on either mean INa
density or INa kinetic properties in isolated myocytes, but clearly reduced INa
density in intracardiac neurons (344551 pA/pF versus control 448561;
mean5SEM, n=11). In addition, the slow component of the current decay (tslow)
at20mVwas accelerated in thepresence ofA-803467 (2.850.3msversus con-
trol 3.450.4 ms; mean5SEM, n=5) and V1/2 of voltage-dependent inactivation
was shifted by 9.6 mV (73.652.0 mV versus control 64.051.6 mV;
mean5SEM, n=5). This is consistent with a reduction in slowly inactivating
brain-type sodium current with depolarized voltage-dependent inactivation. In
AP measurements A-803467 did not affect cardiomyocyte upstroke velocity,
but reduced AP firing frequency in intracardiac neurons by 50%.
